AXON enters the back half of June with short interest at its highest level in months, yet the stock just snapped back 5.6% in a single session — a combination that makes the positioning story genuinely worth watching.
The short-side rebuild has continued at pace since the last note. SI has now climbed 24% over the past month to 5.3% of the free float, with roughly 4.2 million shares estimated short. The week-on-week addition of another 5% confirms the trend is intact: shorts that covered into the May earnings spike — when the stock jumped 14% on the day and 31% over the following five sessions — have been steadily re-entering. The rebuild is consistent and methodical, not a one-day spike. Yet the borrow market flatly refuses to validate the bearish thesis. Availability is running near 490%, meaning almost five shares remain available to lend for every one already borrowed. That is tighter than the 700%-plus level seen in late May, but still firmly in "normal" territory. Cost to borrow is 0.55%, up only modestly on the week. There is no squeeze setup here.
The Street's view is more constructive than the short-side activity implies, though with clear caveats. The analyst note data is dated — the most recent changes are from early May, following the Q1 print — but the direction is worth flagging. Most firms maintained positive ratings and raised or modestly trimmed targets. JP Morgan lifted its target to $755 while keeping Overweight. Barclays and UBS both cut targets, to $523 and $440 respectively, while holding their existing ratings. The mean consensus target around $662 sits well above the current $433 price, though that gap partly reflects the stock's sharp pullback from post-earnings highs rather than a fresh re-rating. Options positioning is roughly neutral — the put/call ratio at 1.08 is barely above its 20-day average of 1.07, a z-score of just 0.44 — so there is no unusual hedging activity building ahead of the August 4 earnings date, at least not yet.
The ownership picture adds an interesting subplot. Patrick Smith, the company's founder, remains among the top five holders with roughly 3.8% of shares. Earlier this month President Joshua Isner sold approximately 5,000 shares in a series of tranches on June 5, generating around $2.4 million in proceeds at prices near $490 — a level now well above the current $433. The insider 90-day net remains positive at $44 million, suggesting the broader insider picture is not one of wholesale distribution. However, the Isner sales came at prices 13% above current levels, which matters as context for the short rebuilding that followed.
The earnings history reinforces why both bulls and bears are paying attention to the August print. The last two reports each produced double-digit one-day moves — 14.7% and 12.2% — though the five-day follow-through diverged sharply, with the most recent delivering 31% and the one before essentially flat. That kind of asymmetry keeps both sides engaged. The ORTEX short score has edged up to 46.7 from 43.4 two weeks ago, a modest but consistent drift higher that mirrors the gradual SI rebuild. The antitrust lawsuit noted in recent coverage remains the headline bear case; whether the August print changes the valuation math is the question that will likely reset the positioning dynamic either way.
With availability still deep, cost to borrow negligible, and no options skew signalling urgency, the setup reads as a measured, thesis-driven short rebuild rather than a momentum pile-on — the August 4 earnings date is when that positioning will face its next real test.
See the live data behind this article on ORTEX.
Open AXON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
